Alnylam Pharmaceuticals (ALNY) Other Non-Current Liabilities (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 17 years of Other Non-Current Liabilities data on file, last reported at $9.2 million in Q2 2026.

• Quarterly Other Non-Current Liabilities fell 97.75% year-over-year to $9.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $9.2 million (down 97.75% YoY) and the FY2025 annual result came in at $7.6 million, down 98.44% from the prior year.
• Other Non-Current Liabilities improved to $9.2 million in Q2 2026, from $7.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $486.9 million in Q4 2024 to a low of $7.6 million in Q4 2025.
• A 5-year average of $252.9 million and a median of $268.9 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 139.37% — and 2025, when it slumped 98.44%.
• Tracing ALNY's Other Non-Current Liabilities over 5 years: stood at $212.6 million in 2022, then soared by 45.09% to $308.4 million in 2023, then jumped by 57.87% to $486.9 million in 2024, then tumbled by 98.44% to $7.6 million in 2025, then gained by 20.52% to $9.2 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $9.2 million (Q2 2026), $7.6 million (Q1 2026), and $7.6 million (Q4 2025), per Business Quant data.